CIHR funds CanROC to study Epinephrine Doses in Cardiac Arrest

Congratulations to the CanROC Research Team.

Led by Principal Investigator Paul Dorian in Toronto they have been successful with a $2.5 Million Dollar Grant from CIHR to study Epinephrine Dosing in Cardiac Arrest

The randomized controlled blinded trial will compare standard dosing vs low dose vs placebo.

This current dosing of epinephrine in cardiac arrest has no strong scientific basis. We do not know if it is helpful, harmful or ineffective for long term, neurologically independent survival.

BC will play a prominent role in the study which will involve multiple centers from across the country.